Beate Jahn
Overview
Explore the profile of Beate Jahn including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
52
Citations
754
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jahn B, Bundo M, Arvandi M, Schaffner M, Todorovic J, Sroczynski G, et al.
BMC Gastroenterol
. 2025 Mar;
25(1):170.
PMID: 40082770
Background: White light (conventional) colonoscopy (WLC) is widely used for colorectal cancer screening, diagnosis and surveillance but endoscopists may fail to detect adenomas. Our goal was to assess and synthesize...
2.
Gudi N, Raj E, Jahn B, Siebert U, Brand A
Int J Technol Assess Health Care
. 2024 Dec;
40(1):e78.
PMID: 39690747
Introduction: Digital health technologies have been enhancing the capacity of healthcare providers and, thereby, the delivery of targeted health services. The Southeast Asia Region (SEAR) has invested in strengthening digital...
3.
Breitegger C, Krismer F, Lorenzl S, Schrag A, Jahn B, Knoflach-Gabis A, et al.
Clin Auton Res
. 2024 Jul;
34(3):321-326.
PMID: 38965149
No abstract available.
4.
Al Rabayah A, Al Froukh R, Sawalha R, Al Shnekat M, Jahn B, Siebert U, et al.
Value Health Reg Issues
. 2024 Jun;
43:101004.
PMID: 38935989
Objectives: To assess the cost-effectiveness of maintenance pemetrexed plus best supportive care (BSC) in non-small cell lung cancer patients from a Jordanian healthcare system perspective. Methods: A Markov model with...
5.
Suzumura E, de Oliveira Ascef B, Maia F, Bortoluzzi A, Domingues S, Farias N, et al.
BMJ Open
. 2024 Jun;
14(6):e086603.
PMID: 38851235
Objectives: To map the available methodological guidelines and documents for conducting and reporting benefit-risk assessment (BRA) during health technologies' life cycle; and to identify methodological guidelines for BRA that could...
6.
de Oliveira Ascef B, Gabriel F, Suzumura E, Maia F, Bortoluzzi A, Farias N, et al.
BMJ Open
. 2023 Dec;
13(12):e075333.
PMID: 38072481
Background: Benefit-risk assessment (BRA) is used in multiple phases along the health technology's life-cycle to evaluate the balance between the benefits and risks, as it is fundamental to all stakeholders....
7.
Crispin A, Rehms R, Hoffmann S, Lindoerfer D, Hallsson L, Jahn B, et al.
Dtsch Arztebl Int
. 2023 Oct;
120(46):786-792.
PMID: 37855423
Background: Persons with a positive family history of colorectal cancer (CRC) are more likely than others to develop CRC and are also younger at the onset of the disease. Nonetheless,...
8.
Sroczynski G, Hallsson L, Muhlberger N, Jahn B, Rehms R, Hoffmann S, et al.
Int J Cancer
. 2023 Oct;
154(3):516-529.
PMID: 37795630
Individuals with a family history of colorectal cancer (CRC) may benefit from early screening with colonoscopy or immunologic fecal occult blood testing (iFOBT). We systematically evaluated the benefit-harm trade-offs of...
9.
Sturzlinger H, Conrads-Frank A, Eisenmann A, Invansits S, Jahn B, Janzic A, et al.
Ger Med Sci
. 2023 Jul;
21:Doc06.
PMID: 37426885
Background: Stool DNA testing for early detection of colorectal cancer (CRC) is a non-invasive technology with the potential to supplement established CRC screening tests. The aim of this health technology...
10.
Kuhne F, Schomaker M, Stojkov I, Jahn B, Conrads-Frank A, Siebert S, et al.
Ger Med Sci
. 2023 Feb;
20:Doc12.
PMID: 36742460
Objectives: Public health decision making is a complex process based on thorough and comprehensive health technology assessments involving the comparison of different strategies, values and tradeoffs under uncertainty. This process...